08/09/22 7:00 AMNasdaq : TNXP conferenceslow floatTonix Pharmaceuticals to Present at the 2022 Virtual Q3 Investor SummitTonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a clinical-stage biopharmaceutical company, announced today that Seth Lederman, M.D., Chief Executive Officer of Tonix Pharmaceuticals, will present at the Virtual Q3 Investor Summit on Tuesday,RHEA-AIneutral
08/02/22 7:00 AMNasdaq : TNXP low floatTonix Pharmaceuticals Receives Federal Grant from the National Institute on Drug Abuse (NIDA) to Advance Development of TNX-1300 as a Treatment for Cocaine IntoxicationThere is No FDA-Approved Product for Cocaine Intoxication TNX-1300 Has Been Granted Breakthrough Therapy Designation by the FDA Phase 2 Single-Blind, Placebo-Controlled, Potential Pivotal Study Expected to Start in Fourth Quarter 2022, Pending FDA Agreement CHATHAM, N.J., Aug. 02, 2022 (GLOBERHEA-AIpositive
08/01/22 7:00 AMNasdaq : TNXP low floatTonix Pharmaceuticals Announces Issuance of U.S. Patent Covering Potentiated Intranasal Oxytocin (TNX-1900) for the Treatment of PainTonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a clinical-stage biopharmaceutical company, announced today that theRHEA-AIneutral
07/28/22 7:00 AMNasdaq : TNXP low floatTonix Pharmaceuticals Announces Collaboration with Kenya Medical Research Institute to Develop TNX-801 in Kenya as a Vaccine for the Prevention of Monkeypox and Smallpox InfectionTonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), aRHEA-AIneutral
07/25/22 7:00 AMNasdaq : TNXP managementlow floatTonix Pharmaceuticals Announces Appointment of Sina Bavari, Ph.D. as Executive Vice President, Infectious Disease Research and DevelopmentTonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced the appointment of Sina Bavari, Ph.D. as its new Executive Vice President, Infectious Disease Research andRHEA-AIneutral
07/11/22 7:00 AMNasdaq : TNXP low floatTonix Pharmaceuticals Announces Development of TNX-601 ER, a Potential Abuse Deterrent, Extended-Release Formulation of Tianeptine Oxalate for the Treatment of Major Depressive DisorderNaloxone-Free Formulation of Tianeptine is an Extended-Release Tablet that Includes Inactive Ingredients and Compression Properties Designed to Confer Abuse Deterrence Once-Daily Tablet Formulation of Tianeptine is Bioequivalent to the Three Times a Day Antidepressant Marketed in Europe for Over 30RHEA-AInegative
07/06/22 7:00 AMNasdaq : TNXP low floatTonix Pharmaceuticals Announces Presentation at the World Orphan Drug Congress USATonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced it will present at the World Orphan Drug Congress USA 2022 being held July 11-13, 2022 at the Hynes Center inRHEA-AIneutral
06/27/22 7:00 AMNasdaq : TNXP clinical triallow floatTonix Pharmaceuticals Announces Trial Design of New Phase 2 Clinical Study of TNX-1300 for Cocaine IntoxicationNew Trial Design is Single-Blind, Placebo-Controlled, Potential Pivotal Study, Pending FDA Agreement Expected to Include Women Based on Reproductive Toxicology Studies, Pending FDA Agreement Planning to Include Patients Who Have Received Naloxone to Increase Enrollment CHATHAM, N.J., June 27, 2022RHEA-AIneutral
06/22/22 7:00 AMNasdaq : TNXP low floatTonix Pharmaceuticals Announces Pricing of $30 Million Private Placement of Convertible Redeemable Preferred StockTonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a clinical-stage biopharmaceutical company, today announced that it has entered into a securities purchase agreement with certain institutional investors to purchase 2,500,000 shares of Series ARHEA-AIneutral
06/21/22 7:00 AMNasdaq : TNXP low floatTonix Pharmaceuticals Announces Publication of Paper in Pharmaceutics on the Enhancing Effect That Magnesium Contributes to in vivo Intranasal Oxytocin AnalgesiaIntranasal Oxytocin with Magnesium Demonstrated Augmented Craniofacial Analgesia in an Animal Model Enhanced Effect of Mg 2+ is the Core Patented Technology of TNX-1900 for Migraine TNX-2900 Orphan Drug Designated Product for Prader-Willi Syndrome Also Contains Mg 2+ Issued Patents Expected toRHEA-AIpositive